Status:
TERMINATED
Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
Lead Sponsor:
Yonsei University
Conditions:
Left-sided Pancreatic Cancer
Ductal Adenocarcinoma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
When distal pancreatectomy is carried out for left-sided pancreatic cancer, splenectomy is usually performed not only for margin-negative resection but also for effective clearance of the splenic hila...
Eligibility Criteria
Inclusion
- Ductal adenocarcinoma
- Age ≥20 and ≤80
- General performance status: the Karnofsky score\> 70% or ECOG 0-1
- Potentially Curative resection
- Tumor size \< 3cm
- Pancreatic cancer located on neck or body portion
- No invasion to spleen or spleen hilum
- No combined resection except Lt. adrenal gland
- Distance more than 5cm (≥5cm) between tumor lateral margin and spleen hilum
Exclusion
- Unresectable or locally advanced, metastatic case
- Patients who do not want surgery
- ASA (American society of anesthesiologists' physical status classification) score: ≥3
- Patients with drug or alcohol addiction
- Patients showing low compliance
- Patients who not want to involve the clinical trial
- Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01875198
Start Date
April 1 2013
End Date
April 1 2014
Last Update
November 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, Seoul, South Korea, 120-752